Bayer Highlights Phase III Data and Related Radiology Technologies at ECR 2026
Bayer will present new developments from its radiology portfolio at the European Congress of Radiology (ECR) 2026, taking place March 4–8 in Vienna, Austria. The company will highlight progress across its contrast agent and injector pipeline, along with data-driven connectivity solutions aimed at improving workflow efficiency and clinical decision-making.
Bayer’s scientific sessions will feature new findings from the clinical development program for gadoquatrane, an investigational low-dose macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI. Presentations will include Phase III subgroup data on abdominal and cardiac MRI, magnetic resonance angiography (MRA), and new analyses from Phase II and Phase III studies in central nervous system (CNS) imaging, alongside pharmacokinetics data.
Across the program, gadoquatrane was evaluated at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a 60% reduction compared with macrocyclic gadolinium-based contrast agents dosed at 0.1 mmol Gd/kg.
The sessions follow Bayer’s 2025 announcement of positive topline results for all studies in its pivotal Phase III QUANTI program. The company has submitted marketing authorization applications for gadoquatrane globally, including Japan, the U.S., the EU, and China, with additional markets expected in the coming months.
“We are delighted to join this year’s European Congress of Radiology, a premier global forum for us to engage with the community as a place where scientific exchange, education, collaboration and innovation converge to improve patient care,” said Nelson Ambrogio, President Radiology, Bayer. He added that Bayer is “proud to showcase cutting edge science” and advance technologies that support clinicians in daily practice.
Minerva Becker, ECR 2026 Congress President, emphasized the role of collaboration in driving progress, stating, “ECR 2026 is driven by the belief that scientific progress in radiology depends on open exchange and strong collaboration.” She noted that industry contributions grounded in clinical science and technology development help translate innovation into patient benefit.